MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
Aethlon Medical EBITDA 2011-2026 | AEMD
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Aethlon Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9 M | -12.3 M | -11.7 M | -10.3 M | -7.85 M | -5.9 M | -5.97 M | -4.8 M | -6.07 M | -4.35 M | -3.96 M | -3.03 M | -3.56 M | -3.1 M | -4.54 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.03 M | -12.3 M | -6.42 M |
Quarterly EBITDA Aethlon Medical
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -1.71 M | - | - | - | -2.53 M | - | - | - | -3.32 M | - | -2.85 M | -3.5 M | -2.88 M | - | -2.53 M | -6.54 M | -4.03 M | - | -2.44 M | -2.41 M | -1.75 M | -1.4 M | -876 K | -860 K | -1.7 M | -1.56 M | -1.96 M | -1.94 M | -1.33 M | - | -1.16 M | -1.24 M | -1.15 M | - | -1.24 M | -4.57 M | -3.34 M | - | -1.08 M | -3.27 M | -2.2 M | - | -1.09 M | -2.83 M | -1.76 M | - | -1.23 M | -2.23 M | -1.01 M | - | -937 K | -2.72 M | -1.79 M | - | -341 K | -2.24 M | -1.91 M | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -341 K | -6.54 M | -2.13 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | USA |
 |
Tactile Systems Technology
TCMD
|
35.9 M | $ 26.39 | -1.46 % | $ 604 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | USA |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
Tandem Diabetes Care
TNDM
|
26 M | $ 21.64 | -7.2 % | $ 1.47 B | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
CONMED Corporation
CNMD
|
120 M | $ 35.8 | -2.29 % | $ 1.11 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-61 M | $ 2.21 | -2.64 % | $ 130 M |  Israel |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | Israel |
 |
NanoVibronix
NAOV
|
-3.58 M | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
10.7 M | $ 24.35 | -0.41 % | $ 206 M | USA |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Viemed Healthcare
VMD
|
51.6 M | $ 9.26 | 0.43 % | $ 360 M | USA |
 |
Varex Imaging Corporation
VREX
|
-4.6 M | $ 10.78 | - | $ 446 M | USA |
 |
Outset Medical
OM
|
-62.4 M | $ 3.39 | -3.69 % | $ 51.6 K | USA |
 |
Vivos Therapeutics
VVOS
|
-10.6 M | $ 1.17 | -2.03 % | $ 5.87 M | USA |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-15.2 M | $ 0.61 | 0.82 % | $ 33.2 M | USA |
 |
PAVmed
PAVM
|
-65.9 M | $ 8.77 | -1.9 % | $ 63.4 M | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |
 |
InspireMD
NSPR
|
426 M | $ 1.67 | -3.47 % | $ 107 M | Israel |
 |
Beyond Air
XAIR
|
-41.5 M | $ 0.67 | -2.84 % | $ 45.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
473 M | $ 11.25 | -1.4 % | $ 1.52 B | USA |
 |
Penumbra
PEN
|
207 M | $ 335.34 | -0.32 % | $ 13.1 B | USA |
 |
Zimmer Biomet Holdings
ZBH
|
2.28 B | $ 87.82 | -1.49 % | $ 17.8 B | USA |
 |
MiMedx Group
MDXG
|
78.8 M | $ 3.82 | -3.05 % | $ 565 M | USA |
 |
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
-26.5 M | - | 10.0 % | $ 610 K | USA |
 |
Myomo
MYO
|
-13.5 M | $ 0.68 | -0.31 % | $ 28.5 M | USA |
 |
TELA Bio
TELA
|
-33.1 M | $ 0.64 | -14.68 % | $ 30 M | USA |
 |
Inspire Medical Systems
INSP
|
64.9 M | $ 49.12 | -2.54 % | $ 1.44 B | USA |
 |
Pulmonx Corporation
LUNG
|
-52.6 M | $ 1.2 | -3.33 % | $ 48.8 M | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |